A reduced risk of short‐term mortality and cardiovascular events with the use of an SGLT2 inhibitor in patients with diabetes and a high risk of cardiovascular disease has been demonstrated, and an improved prognosis has also been shown in heart failure patients without diabetes who were prescribed an SGLT2 inhibitor.31, 32. Here, SLC5A2 is linked to cardiovascular disorder.